Subscribe to the LRG Newsletter 2023View December NewsletterView August Newsletter- GAD Highlights, Life Fest 2024 news & more!View April Newsletter 2022 View December 2022 Newsletter PDF Focus on GDOLs CTOS Sheds [...]
updated 1/20/21 Dr. mOe is an author, survivor, and dynamic mOe-tivational speaker. Diagnosed with GIST in 2012, Dr. mOe believes that God does not waste wounds. She is a freelance journalist, coach, mentor, [...]
Gary Glasser - Board President Steve Pontell - Vice President Kay Stolzer - Secretary Santy DiSabatino - Treasurer Jerry Cudzil - [...]
To search by state, please spell out entire state name. If you would like to print a list, complete your search and then right click on the page to print. If you need additional help, [...]
In this webinar, Dr. Andrew Wagner and Dr. Herbert Loong summarize abstracts and presentations presented during the ASCO22 conference relevant to the GIST patient community.
Our theme for 2021 was It's Time. The year challenged us all, but most especially our patients and caregivers who were striving to survive this rare cancer.
The newest GISTer to join the ranks of LRG Global Representatives is Nandini Dabbir of Hyderabad, India. She is a the Friends of Max City Chapter Leader & GIST Advocate working with the LRG to support GIST patients on their journey.
CTOS 2020 was conducted virtually from November 18th through the 21st, given the nature of our current environment, much of the content of the conference centered on COVID-19 and its impact on cancer patients, but there were a number of sessions and presentations and posters devoted to GIST as well.
This discussion reviewed CRCI in general, and how a person who is being treated for GIST could be affected. We also talked about strategies that can help ameliorate CRCI, new research on CRCI and GIST. we also gave advice on how cancer survivors can best cope with and care for themselves during this unusual global health event.
The FDA granted the approval of Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC), The FDA has also granted accelerated approval to Rozlytrek for the treatment of [...]
If you didn't find what you were looking for, try a new search!
